BAILII is celebrating 24 years of free online access to the law! Would you consider making a contribution?

No donation is too small. If every visitor before 31 December gives just £5, it will have a significant impact on BAILII's ability to continue providing free access to the law.
Thank you very much for your support!



BAILII [Home] [Databases] [World Law] [Multidatabase Search] [Help] [Feedback]

United Kingdom Intellectual Property Office Decisions


You are here: BAILII >> Databases >> United Kingdom Intellectual Property Office Decisions >> Merck Co., Inc (Patent) [2009] UKIntelP o03509 (6 February 2009)
URL: http://www.bailii.org/uk/cases/UKIntelP/2009/o03509.html
Cite as: [2009] UKIntelP o03509, [2009] UKIntelP o3509

[New search] [Printable PDF version] [Help]


Merck Co., Inc [2009] UKIntelP o03509 (6 February 2009)

For the whole decision click here: o03509

Patent decision

BL number
O/035/09
Concerning rights in
SPC/GB/02/002
Hearing Officer
Dr L Cullen
Decision date
6 February 2009
Person(s) or Company(s) involved
Merck & Co., Inc
Provisions discussed
Council Regulation (EC) No. 1901/2006; Articles 7, 8, 23, 28, 36 Council Regulation (EC) No. 1768/92; Article 8
Keywords
Extension for Paediatric Testing, Supplementary Protection Certificates
Related Decisions
None

Summary

An application for an extension to the duration of granted SPC/GB/02/002 was made under Article 7 of Regulation (EC) 1768/92 to obtain the reward provided under Article 36(1) of Regulation (EC) 1901/2006 for completing studies on medicinal products in the paediatric population. The preliminary view of the examiner was that this application did not meet the requirements of Article 8(1)(d)(i) of Regulation (EC) 1768/92 as it did not include a copy of the statement of compliance with an agreed completed paediatric investigation plan as referred to in Article 36(1) of EC Regulation (EC) 1901/2006. This view was upheld by the Hearing Officer who considered the relevance of Articles 8, 23, 28 and 36 of Regulation (EC) 1901/2006 in deciding if the documents provided by the applicant fulfilled the requirement of Article 8(1)(d)(i) of Regulation (EC) 1768/92. An opinion of the Paediatric Committee of the European Medicines Agency (EMeA) on compliance with an agreed completed paediatric investigation plan was considered not to be sufficient as a the statement of compliance with an agreed completed paediatric investigation plan. A copy of an updated marketing authorisation granted by a competent authority under Regulation (EC) 1901/2006 is required. The applicant was allowed a period of time within which to rectify the irregularity with his application.



BAILII: Copyright Policy | Disclaimers | Privacy Policy | Feedback | Donate to BAILII
URL: http://www.bailii.org/uk/cases/UKIntelP/2009/o03509.html